Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
Table 1
Patient demographics.
All IPF patients ()
IPF progressors ()
IPF nonprogressors ()
Other ILDs ()
Healthy controls ()
Sex (% male)
73.8
83.3
67.3
57.6
42.1
Median age at BAL (+range)
73 (51-87)
71.5 (51-85)
73 (57-85)
64 (41-81)
66 (44-70)
BAL tested (%)
63.6
76.7
71.1
56
36.8
BAL baseline % predicted vital capacity (VC)
BAL baseline % predicted TLCO
n/a
Median age at serum (+range)
74 (51-89)
74 (51-89)
74 (52-87)
65 (31-85)
66 (44-87)
Serum tested (%)
76.6
93.3
94.2
78.8
79.0
Serum baseline % predicted vital capacity (VC)
Serum baseline % predicted TLCO
n/a
At the time of analysis, 25 of the 107 IPF subjects had not been followed up for at least 12 months; hence, there are 30 progressors, 52 nonprogressors, and 25 not determined at the time of analysis.
